CorMedix Inc

자세한 내용은 CorMedix Inc 회사

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

회사 정보

종목 코드 CRMD

회사 이름CorMedix Inc

상장일Mar 25, 2010

설립일2006

CEOMr. Joseph Todisco

직원 수64

유형Ordinary Share

회계 연도 종료Mar 25

주소300 Connell Drive

도시BERKELEY HEIGHTS

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호07922

전화19085179500

웹사이트https://cormedix.com/

종목 코드 CRMD

상장일Mar 25, 2010

설립일2006

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Joseph Todisco

Chief Executive Officer, Director

323.43K

-2.01%

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

Dr. Alan William Dunton, M.D.

Independent Director

--

Ms. Elizabeth (Liz) Massonhurlburt

Executive Vice President, Chief Clinical Strategy and Operations Officer

--

Dr. Matthew T. (Matt) David, M.D.

Chief Financial Officer, Executive Vice President

--

Ms. Beth Zelnick Kaufman

Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary

--

이름

이름/직위

직위

주식 보유

변동

Mr. Joseph Todisco

Chief Executive Officer, Director

323.43K

-2.01%

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

수익 분석

FY2024

데이터 없음

지역별USD

이름

수익

비율

United States

43.47M

0.00%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

6.35%

The Vanguard Group, Inc.

5.36%

Elliott Management Corporation

3.60%

State Street Global Advisors (US)

2.27%

Geode Capital Management, L.L.C.

2.11%

Other

80.30%

주주

비율

BlackRock Institutional Trust Company, N.A.

6.35%

The Vanguard Group, Inc.

5.36%

Elliott Management Corporation

3.60%

State Street Global Advisors (US)

2.27%

Geode Capital Management, L.L.C.

2.11%

Other

80.30%

주주 유형

주주

비율

Investment Advisor

13.86%

Investment Advisor/Hedge Fund

13.60%

Hedge Fund

5.69%

Research Firm

1.60%

Sovereign Wealth Fund

1.39%

Individual Investor

1.19%

Pension Fund

0.45%

Bank and Trust

0.30%

Venture Capital

0.06%

Other

61.88%

기관 주식 보유

마지막 업데이트: Mon, Feb 24

보고 기간

기관 수

보유 주식

비율

변동

2025Q1

262

29.51M

43.73%

+3.54M

2024Q4

252

24.74M

40.82%

-30.08K

2024Q3

228

19.79M

34.25%

-1.78M

2024Q2

217

17.74M

32.28%

-4.09M

2024Q1

218

17.92M

32.60%

-5.73M

2023Q4

217

19.38M

35.35%

-2.82M

2023Q3

208

18.46M

33.68%

-3.54M

2023Q2

197

19.74M

38.10%

+6.18M

2023Q1

190

11.28M

25.34%

-2.76M

2022Q4

191

11.93M

28.90%

-1.83M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

4.20M

6.44%

+868.26K

+26.06%

Dec 31, 2024

The Vanguard Group, Inc.

3.38M

5.18%

+309.51K

+10.09%

Dec 31, 2024

Elliott Management Corporation

2.87M

4.4%

+1.32M

+85.14%

Dec 31, 2024

State Street Global Advisors (US)

1.45M

2.23%

+227.39K

+18.55%

Dec 31, 2024

Geode Capital Management, L.L.C.

1.39M

2.14%

+108.36K

+8.44%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

940.59K

1.44%

+940.59K

--

Dec 31, 2024

UBS Financial Services, Inc.

379.87K

0.58%

+340.35K

+861.30%

Dec 31, 2024

Morgan Stanley & Co. LLC

283.12K

0.43%

+50.06K

+21.48%

Dec 31, 2024

Northern Trust Investments, Inc.

510.89K

0.78%

+100.11K

+24.37%

Dec 31, 2024

16.560USD

CorMedix Inc

16.560

개요

회사